Measuring patient safety in ambulatory care: Potential for identifying medical group drug-drug interaction rates using claims data

American Journal of Managed Care

Volumn 10, Issue 11 I, 2004, Pages 753-759

  Solberg, Leif I ^a   Hurley, Judith S ^b   Roberts, Melissa H ^b   Nelson, Winnie W ^a   Frost, Floyd J ^b   Crain, A Lauren ^a   Gunter, Margaret J ^c   Young, Linda R ^c  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c LOVELACE CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; CLONIDINE; DEXTROPROPOXYPHENE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISULFIRAM; DOXYCYCLINE; ERYTHROMYCIN; FLUCONAZOLE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; ITRACONAZOLE; MEVINOLIN; NITRATE; PHENYLBUTAZONE; PHENYTOIN; SIMVASTATIN; SPIRONOLACTONE; SULFONAMIDE; THEOPHYLLINE; TRIAMTERENE; TRIMETHOPRIM; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

ADULT; ADVERSE DRUG REACTION; AGED; AMBULATORY CARE; ARTICLE; DRUG ANTAGONISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; INSURANCE; MALE; PATIENT CARE; PRIORITY JOURNAL;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AMBULATORY CARE; DRUG INTERACTIONS; DRUG UTILIZATION REVIEW; FEMALE; GROUP PRACTICE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICATION ERRORS; MIDDLE AGED; MINNESOTA; NEW MEXICO; POLYPHARMACY; RISK ASSESSMENT; SAFETY;

EID: 8744280235     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kohn LT, Corrigan J, Donaldson MS for the Institute of Medicine. To Err is Human: Building a Safer Health System. Washington, DC: National Academy Press; 2000.
2. Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med. 2000;5:149-154.
3. Chyka PA. How many deaths occur annually from adverse drug reactions in the United States? Am J Med. 2000;109:122-130.
4. Bedell SE, Jabbour S, Goldberg R, et al. Discrepancies in the use of medications: their extent and predictors in an outpatient practice. Arch Intern Med. 2000;160:2129-2134.
5. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447-450.
6. Miwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies in determining the true incidence of adverse events: the nonsteroidal anti-inflammatory drug story. Arch Intern Med. 1997;157:2129-2136.
7. Petty BG. Identifying and reducing complications of outpatient medications. J Gen Intern Med. 2000;15:207-208.
8. Tafreshi MJ, Melby MJ, Kaback KR, Nord TC. Medication-related visits to the emergency department: a prospective study. Ann Pharmacother. 1999;33:1252-1257.
9. Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ. 1990;2:19-33.
10. Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Drug-related hospital admissions: a review of Australian studies published 1988-1996. Med J Aust. 1998;168:405-408.
11. Pouyanne P, Haramburu F, Imbs JL, Begaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ. 2000;320:1036.
12. Beard K. Adverse reactions as a cause of hospital admission in the aged. Drugs Aging. 1992;2:356-367.
13. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
14. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556-1564.
15. Hartshorn EA. Handbook of Drug Interactions. Hamilton, IL: Drug Intelligence Publications; 1973.
16. Davidson KW, Kahn A, Price RD. Reduction of adverse drug reactions by computerized drug interaction screening. J Fam Pract. 1987;25:371-375.
17. Stanaszek WF, Franklin CE. Survey of potential drug interaction incidence in an outpatient clinic population. Hosp Pharm. 1978;13:255-257, 261, 263.
18. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull. 1998;45:210-213.
19. Mitchell GW, Stanaszek WF, Nichols NB. Documenting drug-drug interactions in ambulatory patients. Am J Hosp Pharm. 1979;36:653-657.
20. Laventurier MF, Talley RB. Incidence of drug-drug interactions in a Medi-Cal population. Cal Pharm. 1972;20:18-22.
21. Jinks MJ, Hansten PD, Hirschman JL. Drug interaction exposures in an ambulatory Medicaid population. Am J Hosp Pharm. 1979;36:923-927.
22. Herr RD, Caravati EM, Tyler LS, Iorg E, Linscott MS. Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med. 1992;21:1331-1336.
23. Bergendal L, Friberg A, Schaffrath A. Potential drug-drug interactions in 5125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci. 1995;17:152-157.
24. Merlo J, Liedholm H, Lindblad U, et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ. 2001;323:428-429.
25. Peng CC, Glassman PA, Marks JR, et al. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm. 2003;9:513-522.
26. Hennessy S, Bilker WB, Zhou L, et al. Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA. 2003;290:1494-1499.
27. Hansten PD, Horn JR. Hansten and Horn's Drug Interactions, Analysis and Management. St. Louis: Facts and Comparisons; 2003.
28. Klasco RK, ed. DRUG-REAX® System. Greenwood Village, Colo: Thomson Micromedex; edition expires 12/2003.
29. Shinn AF, Shrewsbury RP, eds. Evaluations of Drug Interactions® (EDI). San Bruno, CA: First Databank, 2002.
30. Fulda TR, Valuck RJ, Zanden JV, Parker S, Byrns PJ. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res Clin Exp. 2000;61:540-548.
31. Valuck RJ, Byrns PJ, Fulda TR, Zanden JV, Parker S. Methodology for assessing drug-drug interaction evidence in the peer-reviewed medical literature. Curr Ther Res Clin Exp. 2000;61:553-568.
32. Master Drug Data Base (MDDB®). Vol. 2002. Zionville, Ind: Facts and Comparisons/Medi-Span; 2002.
33. Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. DICP Ann Pharmacother. 1990;24:982-989.